rough week for hospital stocks as covid cases continue to spike in several states let's look at bertha coombsh week for hospital stocks. they've been on a tear and really bounced look at the declines this week the big concern is the fact that some of the momentum they've been seeing could now be reversed raymond james, in fact, talking about how they've seen a rebound in states like florida, key states for a lot of these hospital operators hca, tenet health, universal health all up 70% or more in terms of their volumes, up before they were before those states reopened in april but we're seeing spikes of coronavirus in texas and in florida. the concern is we'll have to see these hospitals pare back, and even if they don't shut downie elective surgeries, the question is about patients. that's the big question in all of this, that patients might be scared to come back if they feel there's too many risks of them being exposed to covid in the hospital, kelly. >> right, and i thought it was interesting, too, that they talked about not just the short-term pressure they could suffer from coronavirus

break here and then we will come back and talk about what we're seeing in the markets let's get to bertha coombss well >> this has been an incredible quarter when you look at biotech. but health technology has been right there with those big names that are forging the bath forward. quarter to date up about 29% year to date also seeing really strong gains as well also the best performer in the s&p 500. they make diabetes monitoring measuremen measurements it is a gain in all of last year it is trading at 185 times forward earnings the big players is the telehealth players one medical, none of them is profitable but over at piper sand this morning, they say in a things have goeb well for them over the next three months. take a look at this tweet from an hhs spokesman he says the administration will renew the public health emergency. that has relaxed telehealth rules and made adoption so strong in the next three months. it also bodes well for hospitals as well to continue to get some of the extra reimbursement they are due. stienlly take finally look at some of the names in the biotech tools space.